profits
producing
product
products
prozac
previous
pressures
pharmaceutical
pfizer's
popular
poorly
patents
performed
slide
sale
sales
said
short
shares
selling
spending
staple
strong
strength
at
as
and
annoucement
anti-depressant
another
also
alongside
although
apace
are
india's
indian
intensified
ingredients
it
its
is
dr
drug
drugmaker
drugs
december
decrease
development
due
down
reddy
reddy's
research
reputation
representing
recent
rose
rupees
run
rights
rising
r&d
fell
flagged
firm
firm's
for
famous
fall
face
from
future
93%
966m
costs
competition
competitive
competitors
company
court
continuing
case
cause
the
they
three
that
than
to
too
were
well-known
which
whose
was
won
with
40m
4.7bn
$915,000
Â£486,000
months
most
more
marketing
march
maker
manufacturers
on
of
out
opportunity
other
8%
8.6%
has
had
hypertension
home
heavy
built
but
business
big-name
banning
both
generic
generics
gathering
version
versions
new
near
norvasc
number
launches
lilly
listed
lost
2000
2004
25%
exclusive
eli
europe
key
us
37%
705m
-
york
year
1.4bn